Novantrone and Breastfeeding
The manufacturer of Novantrone (mitoxantrone) recommends that women not breastfeed while using this medicine. It is known to pass through breast milk in large amounts. Although Novantrone has not been adequately studied in women who are nursing, it is associated with potentially dangerous problems, such as infections and heart problems, which may also affect a breastfed infant.
Novantrone® (mitoxantrone) is a prescription chemotherapy medication used to treat certain cancers. It is also used in the treatment of multiple sclerosis.
Novantrone passes through breast milk in humans. The manufacturer recommends that women not breastfeed while receiving it. If you are breastfeeding or plan to start, talk with your healthcare provider before receiving this medication.
Novantrone has been shown to pass through breast milk in humans. In addition, significant amounts of the medicine have been shown to be present in breast milk as long as 28 days after the last dose was given. This is because Novantrone accumulates in the body after repeated doses, and is slowly removed from the body.
The potential effects of Novantrone in a breastfed infant have not been studied. However, the drug is associated with serious side effects, including heart problems and an increased risk for infections. Because of the side effects associated with its use, and because it is found in breast milk in relatively large amounts, Novantrone should generally not be used by women who are breastfeeding.
You should discuss breastfeeding and Novantrone use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.
If you would like to breastfeed and have been treated with this medication, talk to your healthcare provider about how long you should wait to start breastfeeding after receiving your last dose.